Michael Okunewitch
Stock Analyst at Maxim Group
(0.52)
# 4,171
Out of 5,162 analysts
26
Total ratings
23.08%
Success rate
-18.78%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNRX VolitionRx | Downgrades: Hold | n/a | $0.19 | - | 1 | Dec 3, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $5 → $10 | $1.32 | +657.58% | 1 | Oct 20, 2025 | |
| CTOR Citius Oncology | Upgrades: Buy | $6 | $0.81 | +638.55% | 3 | Sep 23, 2025 | |
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $0.52 | +6,681.63% | 2 | May 29, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $4.80 | +150.00% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $16 → $28 | $1.83 | +1,430.05% | 2 | Feb 20, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $1.61 | +86.34% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $2.48 | +61.29% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.31 | +3,741.23% | 1 | Sep 24, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $0.97 | +516.33% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $0.70 | +1,614.29% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.62 | +1,381.48% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $2.09 | +761.24% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $2.04 | +99,164.71% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $16.58 | +50.78% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.30 | +1,880.85% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.69 | +577.51% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $0.96 | +10,292.85% | 1 | Nov 30, 2021 |
VolitionRx
Dec 3, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.19
Upside: -
Rani Therapeutics Holdings
Oct 20, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $1.32
Upside: +657.58%
Citius Oncology
Sep 23, 2025
Upgrades: Buy
Price Target: $6
Current: $0.81
Upside: +638.55%
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $0.52
Upside: +6,681.63%
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $4.80
Upside: +150.00%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $16 → $28
Current: $1.83
Upside: +1,430.05%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.61
Upside: +86.34%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $2.48
Upside: +61.29%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.31
Upside: +3,741.23%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.97
Upside: +516.33%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $0.70
Upside: +1,614.29%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $1.62
Upside: +1,381.48%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $2.09
Upside: +761.24%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $2.04
Upside: +99,164.71%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $16.58
Upside: +50.78%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $0.30
Upside: +1,880.85%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $3.69
Upside: +577.51%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $0.96
Upside: +10,292.85%